Skip to main content
. 2021 Jun 24;12:3950. doi: 10.1038/s41467-021-24273-8

Fig. 3. Milk-derived EVs reduce tumor burden.

Fig. 3

a SW620 colorectal cancer cells were treated with RM EVs (20 μg/mL) and colonies were quantified (n = 3). b Apoptosis of SW620 colorectal cancer cells at 72 h after treatment with RM EVs (20 μg/mL; n = 3). c Apoptosis of LIM1215 colorectal cancer cells at 72 h after treatment with RM EVs (20 μg/mL; n = 3). d Apoptosis of human embryonic kidney (HEK293) cells at 72 h after treatment with RM EVs (++ = 50 μg/mL; n = 3). e Schematic representation of colorectal cancer xenograft experiment. f Tumor volume of SW620 xenografts measured after oral administration of PBS and CM EVs (25 mg/kg; n = 3). g SW620 tumor-bearing mice were orally administered with a single dose of DiR-labeled EVs (25 mg/kg). IVIS imaging of the harvested tumor tissue after 24 h of EVs administration is displayed. h Tumor volume of 4T1.2 bearing mice after oral administration of PBS, CM EVs (25 mg/kg), WM (70 µL), and EV-depleted milk (n = 5). i 4T1.2 cells were treated with CM EVs (100 and 200 µg/mL) for 72 h and injected into Balb/c mice. j Tumor volume of 4T1.2 cells treated with and without CM EVs (n = 5). All data are represented as mean ± s.e.m. Statistical significance was determined by unpaired two-tailed t-test.